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ABSTRACT 
OBJECTIVE: The objective of this systematic review is to determine whether or not 
Vitamin E is effective in reducing the mortality related to cardiovascular event in 
patients with Type 2 Diabetes mellitus. 
STUDY DESIGN: Review of three English language primary studies published from 
2004 to 2010. 
DATA SCOURCE: Randomized, double blind, placebo-controlled trails comparing 
Vitamin E to Vitamin C, n-polyunsaturated fatty acid and placebo were found using 
Ovid MEDLINE and Cochrane database 
OUTCOME MEASURED: The primary outcomes measure by all three studies included 30-
day cardiac mortality, mortality due to CHF and nonfatal myocardial infarction and 
stroke. The secondary outcomes measured in the studies included hospitalization forCHF 
and coronary revascularization 
RESULTS: Three double-blind randomized controlled trails were incorporated in 
this review. Study by Milman et al showed that Vitamin E supplementation is 
beneficial compared to the placebo group. The second study by Jaxa-Chameic et al. 
showed that Vitamin E is beneficial along with Vitamin C but is not effective when 
used alone. The third study by Marchioli et al. showed that Vitamin E treatment has 
a statistically nonsignificant (p = 0.18) increased risk of developing CHF. 
CONCLUSIONS: The result of one ofthe three RCT's showed that use of Vitamin E 
supplementation provides cardiovascular benefits in diabetic population with Hp 2-
2 genotype. The other two studies showed worse effects or no conclusive effects 
with Vitamin E supplementation. The study population with favorable outcome with 
Vitamin E supplementation included Diabetic patients with Hp 2-2 genotype. Hence, 
further studies must be conducted in population with Hp 2-2 genotype to conclude 
the effects of Vitamin E. 
KEY WORDS: Vitamin E, antioxidants, Myocardial Infarction, Diabetes Mellitus, 
Prophylaxis 
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INTRODUCTION 
Cardiovascular disease is a major cause of morbidity and mortality in patients with 
Type 2 Diabetes Mellitus (T2DM). T2DM is the most common form of metabolic disorder 
commonly seen in obese population.! Diabetic patients are chronically exposed to high 
blood glucose levels which in the long run leads to increased deposits of lipids in the intima 
of the blood vessels. These deposits lead to narrowing of the vessel, affecting the blood flow 
and ultimately resulting in an increased risk of clogging and hardening of the vessels. 
Hyperlipidemia, also commonly seen in diabetic patients, leads to atherosclerotic changes 
of the arteries of the heart causing coronary artery disease (CAD), the most common cause 
of acute myocardial infarction (AMI) and congestive heart failure (CHF). 
Diabetes Mellitus is an independent risk factor of cardiovascular diseases and tends 
to develop heart disease and stoke at an earlier age.! In the article by Jaxa-Chamiec, it is 
proposed that reactive oxygen species (ROS) along with hyperglycemia plays a crucial role 
in endothelial dysfunction, ischemia reperfusion injury and pathogenesis of DM.2 
Endothelial dysfunction leads to decreased production of nitric oxide (NO). NO is an 
endothelium-derived relaxing factor (EDRF) which signals smooth muscle to relax causing 
vasodilation of the blood vessel. Hence, decrease in NO causes vasoconstriction and 
decrease perfuSion to organs and tissues. Population with diabetes, hypertension and 
atherosclerosis are noted to have decreased amount of NO. In 2004, death due to 
cardiovascular complication in diabetic population of ages 65 years or older was around 
68%.1 
Diabetic population has atypical presentation of AMI or no symptoms due to 
autonomic nerve dysfunction known as "silent heart attack". The classic presentation of 
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AMI includes symptoms of severe substernal chest pain/pressure sometime radiating to 
the left upper extremity, jaw or shoulder; nausea, vomiting, diaphoresis, dizziness, 
shortness of breath or general malaise. The heart myocardium is damaged in MI leading to 
decreased compliance of the heart ultimately reducing the contractility and stroke volume. 
AMI is the common cause of heart failure. The population with CHF requires frequent 
hospitalizations increasing the cost of care. In United States, between 2009 - 2034, cost of 
care for cardiovascular disease is estimated to increase from $113 billion to $336 billion.1 
Since there is no definite treatment for cardiovascular complications in diabetic patients, 
most of the money is spend to prevent further complications and to stabilize patient's 
condition. 
T2DM is a chronic disease that requires constant monitoring and drug intervention. 
T2DM population receives aspirin, clopidogrel, B-blocker to prevent AMI or stroke and 
receive Angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers 
(ARBs), B-blockers, digoxin, and diuretics in various combinations to control the severity of 
the heart failure.2 However, the diabetic population is not treated to reduce the reactive 
oxidative species (ROS), which leads to endothelial damage. Vitamin E is known to have an 
antioxidant property that is theoretically known to decrease ROS levels and hence the 
study was proposed to see the effects of Vitamin E on cardiovascular disease in diabetic 
patients. 
The topic of study is important to health care providers working in any specialty 
because diabetes is a common condition today with high rates of incidence and prevalence. 
It is proposed that between 2009-2034, diabetic patients will increase from 23.7 million to 44.1 
million,! Also, if the study intervention shows to have positive effects in T2DM patients, the 
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cost associated with care in this population can be reduced. If supplemental Vitamin E 
shows to reduce the incidence of AMI and severity of CHF, it will reduce the cardiovascular 
related hospitalization cost in T2DM population. 
OBJECTIVE 
The objective of this systematic review is to determine whether or not the use of 
Vitamin E supplementation is effective in reducing the cardiovascular mortality in Type 2 
Diabetes Mellitus (T2DM) patients. 
METHODS 
The three studies included in this review were based on a following criterion. The 
population included individuals with Type 2 Diabetes Mellitus and acute myocardial 
infarction with or without T2DM. Study by Milman et aL further classified the diabetic 
population depending on their genotype: Haptoglobin (Hp). The study included the diabetic 
patients with Hp 2-2 genotype only. 
All studies excluded patients with uncontrolled hypertension, stroke within 1 month 
before enrollment, unwillingness to stop antioxidants supplements, known allergy to 
vitamin E. In addition, the study by Milman et aL excluded diabetic population with Hp 1-1 
and Hp 2-1 genotype; Jaxa-Chamiec et aL excluded the death due to non-cardiac related 
cause and Marchioli et aL excluded population with baseline CHF managed by multiple 
drug regimen. 
The intervention used in the studies was Vitamin E 300 mg/ day (Marchioli et aLl, 
600 mg/day (Jaxa-Chamiec et aL) and 400 IU/day (Milman et aLl. The treatment groups 
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were compared to the control groups who were given visually matched n-polyunsaturated 
fatty acid 19/day (Marchioli et al.), Vitamin C 1200 mg/day (Jaxa-Chamiec et al.) and 
placebo. The main outcomes measured were mortality related to cardiovascular events, 
risk of developing CHF and hospitalization for cardiovascular complication (PEOM). The 
studies were double blind, randomized, and placebo-controlled. 
The study performed by Jaxa-Chamiec et al. were given infusion and oral Vitamin E 
and Vitamin C together and other group on the study was given infusion of saline placebo.2 
In the study performed by Marchioli et al. the population was divided into four 
groups who were given Vitamin E, n-polyunsaturated fatty acids, both or none respectively 
and were followed for 3.5 years.3 Echocardiographic measure ofleft ventricular ejection 
fraction was determined and patients developing CHF were defined as "hospitalization or 
death for CHF".3 
The study performed by Milman et al. took place within 47 primary health care 
clinics in the Haifa and Western Galilee district of Clalit Health Services.4 Hp phenotyping 
was performed by electrophoresis and diabetic population with Hp 2-2 were selected. A 
computer generated randomization was used to divide study population into 2 groups 
from with one group received Vitamin E and another group received placebo.4 
Key words used in literature searches were vitamin E, antioxidant, congestive heart 
failure, myocardial infarction, diabetes mellitus and oxidative stress. All articles were 
published in English language in the peer-reviewed journals. Articles used in the review 
were searched and selected by the author using literature searches like Ovid, Medline and 
Cochrane. Articles were selected based on their relevance and outcomes. The studies 
included are conducted in randomized, controlled fashion in a prospective, intention to 
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treat basis, date after 2004 or later. The statistics utilized in the studies were p-value, 
confidence interval (CI), relative risk reduction (RRR), absolute risk reduction (ARR) and 
number needed to treat (NNT). 
T bl 1 D a e - h· &Ch emograpl ICS f· I d d d· aractenstlcs 0 mc u e stu les 
CHARACTERISTICS OF STUDIES INCLUDED IN SYSTEMATIC REVIEW OF THE 
ADDITION OF VITAMIN E IN THE REGIMEN OF MYOCARDIAL INFARCTION 
Study Type #Pts Age Inclusion Exclusion WID Intervention 
(yrs) criteria Criteria 
. Jaxa- Randomized, 800 50 - In-hospital or Documented 0 VitaminE 
Chamiec, placebo- 75 out-hospital non-cardiac 600 mg/day; 
2005 (1) controlled cardiac cause 
double-blind mortality in Vitamin C 
clinical study patients with 1200 
or without mg/day 
diabetes 
mellitus 
Marchioli Open label, 8415 45 - No diagnosis Heart failure at 220 VitaminE 
2006 (2) randomized, 70 of heart baseline; use of 300 mg/day; 
clinical trial failure and angiotensin-
an converting n-3 
echocardio- enzyme polyunsatur 
graphic inhibitors, ated fatty 
measurement B-blockers, acids I g/day 
of Ejection diuretics or 
Fraction (EF) nitrates for 
at baseline CHF 
management. 
Milman, Prospective, 1434 ;:0:55 ;:0:55 yo Hp I-I & 2-1 136 VitaminE 
2008 (3) Double- T2DM and genotypes; 400 IU/day; 
blinded Hp2-2 Uncontrolled 
clinical trial genotype, hypertension; 
MI or stroke 
within 1 month 
before 
enrollment; 
unwillingness 
to stop 
antioxidant 
supplements; 
Known allergy 
to Vitamin E 
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OUTCOME MEASURED 
The primary outcome measured was incidence of the cardiovascular morbidity and 
mortality in the study population. Jaxa-Chamiec et al. measured the primary outcome based on 
30-day cardiac mortality in-hospital or out-hospital. Marchioli et al. measured the risk of 
developing congestive heart failure by performing echocardiogram measurement of the ejection 
fraction and defined the population developing CHF during the study as "death or hospitalization 
due to CHF". Study performed by Milman measured primary outcome based on composite of 
cardiovascular death, nonfatal myocardial infarction and stroke. Milman also measured the 
secondary outcomes, which included total mortality, hospitalization for congestive heart failure 
and coronary revascularization. 
RESULTS 
The results pertaining to the primary outcome were documented as dichotomus data in all 
three studies. The data from the studies was published as an intention to treat analysis with the 
exception of participants who did not participate till the end of the study or those who were lost 
to follow-up or incompliant. 
Jaxa-Chamiec et al. reported cardiovascular mortality of 8% and 22% in the Vitamin E 
and control groups (Vitamin C), respectively. This difference is statistically significant (p = 
0.036). The absolute risk reduction (ARR) was calculated to be 14% and the relative risk 
reduction (RRR) was 175%. This study determined that munber needed to treat (NNT) was 7 
patients using the dosage of 600 mg/day (Table 2). 
Marchioli et al. reported hospitalization and death due to congestive heart failure of 4.7% 
and 2.2% in the Vitamin E and control groups (n-polyunsaturated fatty acid), respectively. This 
difference is statistically nonsignificant (p = 0.18). The treatment with Vitamin E in this study 
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showed increased risk of developing CHF. The absolute risk reduction (ARR) was calculated to 
be 2.5% and the relative risk reduction (RRR) w~ 53%. This study determined that number 
needed to treat (NNT) was 40 patients using the dosage of 300 mg/day (Tabie 2). 
Milman et al. reported cardiovascular death, nonfatal myocardial infarction and stroke of 
1.6% and 4.6% in the Vitamin E and control groups, respectively. This difference is statistically 
significant (p = 0.003). The absolute risk reduction CARR) was calculated to be 3% and the 
relative risk reduction (RRR) was 187.5%. This study determined that number needed to treat 
(NNT) was 33 patients using the dosage of 400 IU/day (Table 2). 
Table 2- Efficacy of Vitamin E in cardiovascular mortality 
Study Vitamin E Control p-value 95%CI RRR ARR NNT 
group group 
(CEI{) (EER) 
Jaxa- 8% 22% 0.036 0.51 to 1.85 175% 14% 7 
Chamiec 
Marchioli 4.7% 2.2% 0.18 0.92 to 1.56 -53% -2.5% -40' 
Mi lman 1.6% 4.6% 0.003 0. 16 to 0.70 187.5% 3% 33 
CI - Confidence Interval, RRR - Relative Risk ReductIOn, ARR - Absolute Risk ReductIOn, 
NNT = Number Needed to Treat 
* Since the outcome measured was incidence and severity of cardiovascular disease, the negative 
value for NNT indicates that for every 40 participants who took Vitamin E, there was one fewer 
incidence of cardiovascular complication than in the group of participants taking placebo 
As seen in table 2 the Relative Risk Reduction (RRR) is high in both the Jaxa-Chamiec 
and Milman studies with 175% and 187.5% respectively, however the Marchioli study did not 
show a similar reduction in cardiac mortality with a RRR of 53%. It is also reflected in numbers 
needed to treat (NNT) for Marchioli study is higher compared to the other two studies. 
If compared the doses of Vitamin E used in the three studies, it appears that Jaxa-
Chamiec utilized dose of 600 mg/day is approximately five to six times more effective with a 
;. 
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NNT value of7 compared to dose of 300 mg/day and 400 IU/day used by Marchioli and Milman 
with a NNT value of 40 and 33 respectively. However, there is no data in study that mentions 
compares the dosage of Vitamin E. 
Secondary end points measured in the study by Milman et al. did not show significant 
difference in the group treated with Vitamin E compared to the placebo. The results for the 
secondary end points are listed in Table 3. 
T bl 3 S a e d E dP' tA I . fT t to t econ ary n om nalYS1S 0 rea men u comes. 
End points VitaminE Placebo PValue RRR ARR NNT 
Revascularization 11 (1.5%) 18 (2.5%) 0.17 66% 1% 1 
Congestive Heart Failure 8 (1.1%) 8 (1.1%) 0.96 0 0 0 
Total Mortality 11 (1.5%) 12 (1.7%) 0.77 13% 0.2% 5 
The studies chosen for this review had certain limitations. The study did not include all 
the participants in the results as some were excluded from the study. In the study by Milman et 
aI.136 were not included in the results: two were lost to follow up; seven due to their physician's 
advice; eleven due to side effects, 116 were noncompliant based on telephone interviews. Also, 
in this study, no attempt was made to optimize or manage the medication prescribed by the 
primary care physician. Limitation to Jaxa-Chamiec et aI. study is the retrospective mode of 
analysis performed on the diabetic patient subgroup and the secondary analysis (effects of 
antioxidant Vitamins on patients older than age 70, anterior myocardial infarction, and symptoms 
of AMI for> 12) did not reach significance and hence failed to support the primary hypothesis of 
the study. 
All the clinical trials have failed to test the basic foundation underlying the hypothesis, 
which is the capacity of the antioxidant to reduce the oxidative stress. None of the studies 
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measure the oxidative states in the study population, it is impossible to determine the effect of 
antioxidant supplement without knowing the initial oxidative stress a person is experiencing. It is 
hard to show the effect of a substance without determining what it is actually having the effect 
on in the first place. 
DISCUSSION 
Oxidative modification by reactive oxidative species (ROS) oflow-density lipoprotein is 
an important step in the development and progression of atherosclerotic plaque. ROS are found 
in high quantity in hyperglycemic state of diabetic patients. Increased oxidative stress has been 
linked to impaired endothelial function.2 Vitamin E has antioxidant properties that help reduce 
ROS formation, in turn inhibit the formation of atherosclerotic plaque. Reduction in the 
formation of atherosclerotic and endothelial damage can reduce cardiovascular damage in 
diabetic popUlation. 
According to the study Marchioli et aI., there is a significant relation between plasma 
oxidized low-density lipoprotein and severity as well as worsening ejection fraction and higher 
level of neurohormonal activation in patients with CHF? However, it's effect were not 
reproducible in the study which concluded that Vitamin E leads to depression of myocardial 
function and hospitalization and death in CHF. Hence, Vitamin E did not show a beneficial role 
in prevention of congestive heart failure after a myocardial infarction 
However, the study on Diabetic population with Hp 2-2 genotype by laxa-Chamiec et al 
showed cardiovascular benefits form Vitamin E supplementation. It was concluded that Vitamin 
E reduced cardiovascular death and AMI in the specific population with Hp 2-2 genotype. 
:/ , 
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CONCLUSION 
According Marchioli et al. Vitamin E has deleterious effect on cardiovascular outcomes, 
particularly late-onset heart failure? The study showed a statistically nonsignificant increased 
risk of developing CHF due to depression of left ventricular function with addition of Vitamin E 
supplementation to their therapy. According to Jaxa-Chamiec et al. antioxidative property of 
Vitamin E significantly reduces a 30-day mortality in diabetic patients with recent MI but the 
secondary analysis in a trail failed to support its primary hypothesis and the validity of the trail is 
questionable. However, according to Milman et al. Vitamin E provides cardiovascular benefit to 
diabetic individuals with the Hp 2-2 genotype. Vitamin E supplementation in this population has 
shown to reduce cardiovascular death and myocardial infarction. 
Hence, it can be conclude that Vitamin E is effective in diabetic patients with Hp 2-2 
genotype and can have adverse effect in non-diabetic population. Future research should be 
designed to study the effect of Vitamin E in Hp 2-2 genotype diabetic patients. The research of 
further studies will implement the use if Vitamin E in specific diabetic population. The use of 
Vitamin E in this population can reduce the cost and cardiovascular complications in diabetic 
population. 
g 
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